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Introduction
Colony-stimulating factors (CSFs)' are a heterogeneous group of glycoproteins that are required for the proliferation and differentiation of hematopoietic progenitor cells in vitro. The gene for human granulocyte-macrophage CSF (GM-CSF) has been cloned, and recombinant GM-CSF (rGM-CSF) has been shown to support the growth ofprogenitor cells for granulocytes, erythrocytes, macrophages, megakaryocytes, and eosinophils (1, 2) . In addition to effects on the growth of early progenitor cells, GM-CSF enhances the effector functions of mature cells of the granulocyte-macrophage series. For example, GM-CSF has been shown to inhibit neutrophil migration (3), stimulate neutrophil phagocytosis (4) , and enhance macrophage tumoricidal activity in vitro (5) . The mechanisms whereby GM-CSF induces such that the initial step involves binding ofGM-CSF to specific, high affinity surface receptors that are present on both early myeloid progenitor cells as well as on differentiated cells of the granulocyte-macrophage series (6) .
In an effort to study the mechanisms of action of GM-CSF, we have investigated the effects of this growth factor on the proliferation and differentiation of the U937 monocytic cell line. We report that GM-CSF is inhibitory to the proliferation of U937 cells, and that this inhibition is associated with the secretion of biologically active tumor necrosis factor (TNF). Furthermore, we also show that GM-CSF enhances TNF secretion of normal human blood monocytes that are induced by endotoxin and phorbol myristate acetate (PMA).
Methods
Cell lines and human mononuclear cells. Cell lines used in this study (U937 (7), HL60 (8) , KG-l (9), K562 (10) , and Daudi (11)) were obtained from the American Type Culture Collection (Rockville, MD) and cultured in RPMI 1640 medium (Gibco, Grand Island, NY) that was supplemented with 10% fetal bovine serum (FBS). Peripheral blood cells were obtained from volunteer donors and mononuclear cell suspensions were prepared by Ficoll-Hypaque density gradient centrifugation. T-lymphocytes were depleted by E rosetting to enrich peripheral blood monocytes (E-fraction). The composition of the E-fraction was determined by indirect immunofluorescence staining with monoclonal anti-Mo2, -HLA-DR, -Tl 1, -Bl, and -NKHI (12) antibodies, and was found to contain 75-85% Mo2-,70-80% HLA-DR-, 0-1% TI 1-, 3-5% Bl-, and 5-8% NKH 1-positive cells.
Biological reagents. rGM-CSF was a gift from Dr. S. Clark, Genetics Institute, Cambridge, MA, and had been purified to a single band (-2.5 X 106 pg/ml and 2 X I09 U/mg protein sp act) from medium conditioned by COS cells transfected with the p91203 vector that contained the GM-CSF complementary DNA (cDNA) (1) . Units of colony-stimulating activity were calculated from the dose-response curve of rGM-CSF concentration for normal bone marrow colony growth, with 50 U/ml the concentration that stimulated the formation of 50% maximal colony growth (4) . Human recombinant granulocyte CSF and recombinant macrophage CSF were also provided by Drs. Clark and G. Wong, and were used at final dilutions of 1: 1,000 and 1:500 ofCOS cell supernatant, respectively. These concentrations were found to support the maximum growth of either human granulocyte or murine macrophage colonies in agar culture. Anti-GM-CSF sheep serum, also provided by Dr. Clark, was prepared against purified rGM-CSF and reacted with a single broad band (apparent molecular mass 19-26 kD) by Western blot analysis. For some experiments, "mock" CSF (supernatant from COS cells transfected with vector DNA only) was used for control purposes. The endotoxin concentrations ofstock rGM-CSF, mock CSF, and the medium (RPMI 1640 with 10% FBS) used in this study were 0.5, 0.5, and 0.3 ng/ml, respectively (kindly measured by Dr. R. N. Berzofsky, M. A. Bioproducts, Walkersville, MD). Human recombinant TNF (rTNF, PAC-4D) was generously provided by the Asahi Chemical Industry, Shizuoka, Japan, and had a 2.2 X 106 U/mg sp act as defined by its cytotoxic effects on actinomycin D-treated L929 mouse fibroblast cells (13) . Purified mouse monoclonal anti-TNF antibody (IgGl) was also provided by Asahi Chemical Industry for blocking studies. Monoclonal antibody to interferon-gamma (IFN-gamma) (clone 3C 1I C8, IgG 1) was produced in our laboratory as previously described (14) and used as a control in blocking experiments. I03 U/mI sp act recombinant interleukin 1 (rIL-1) alpha and beta were obtained from Genzyme Corp., Boston, MA. PGE1, indomethacin, lipopolysaccharide (Escherichia coli 011 1:B4), and PMA were purchased from Sigma Chemical Co., St. Louis, MO.
Colony assay. Cell lines were plated at 5 X 102 cells per 1 ml culture in Iscove's modified Dulbecco's minimal essential media (Gibco) that contained 20% FBS and 0.3% agar over an underlayer of 0.5% agar as previously described (15). Indomethacin at a final concentration of I0' M was routinely added to prevent endogenous prostaglandin production.
The effects of rGM-CSF, rTNF, rIL-I alpha and beta, and PGEI on colony growth were assayed in this system during a 7-d incubation period (37°C, 5% CO2). In some experiments, blocking antibodies (anti-GM-CSF, anti-TNF) were added and allowed to incubate for 1 h at 25°C before final plating. At day seven, overlayers were harvested, dried on glass microscope slides, fixed in methanol for 1 min, and stained with Gill's hematoxylin for 15 min (Fisher Scientific Co., Fair Lawn, NJ). Colonies (40 cells) and clusters (8- (20) . Hybridization was performed for 20 h at 60°C in a solution that contained I M NaCl, 1% sodium dodecyl sulfate (SDS), 10% dextran sulfate, 100 ug/ml salmon sperm DNA, and 1 X 106 cpm/ml-labeled probe. The membrane was washed with 2X standard saline citrate (SSC)/1% SDS for I h at 65°C and 0.IX SSC at room temperature for I h (I X SSC = 0.15 M NaCl and 0.015 M Na citrate, pH 7.0). The blots were then dried and used to expose Kodak Xomat x-ray film with intensifying screens.
Measurements ofTNF. For some experiments, the TNF concentration of cell-free supernatant was measured by using a modification of an enzyme-linked immunosorbent assay (ELISA) developed by the Asahi Chemical Industry (21) . Two murine monoclonal antibodies that reacted with separate epitopes on the TNF molecule were utilized. The first antibody was bound to the 96-well plate with 0.05 M Na2CO3, pH 9.5. After incubating the plates at 4°C overnight, they were washed twice with 0.05% Tween in phosphate-buffered saline (PBS). The wells were then blocked for 2 h at 25°C with 20% horse serum to prevent nonspecific binding of the second monoclonal antibody. After washing twice, 200 ml each of TNF standards and test samples were plated in triplicate wells and incubated at 4°C for 18 h. The plates were washed again and the second antibody, bound to horseradish peroxidase, was added. After incubating the plates for 6 h at 25°C, they were washed twice, and 0-phenylenediamine/H202 (Sigma Chemical Co.) in sodium citrate-phosphate buffer (Fisher Scientific Co., Allied Corp.) was added (30 mg 0-phenylenediamine per 20 ml citrate-phosphate buffer, pH 5, with 7 Al 30% H202). The plates were then developed at 25°C for 5 min; the reaction terminated with 4.5 M H2SO4. The absorbance was read at 492 nm on an ELISA Reader (Bio-Rad Laboratories, Richmond, CA) and a standard curve was computed. The TNF concentration in test samples was determined from the standard curve and expressed as units per milliliter, with I U/ml TNF defined as the amount necessary to kill 50% of actmonycin D-treated L929 mouse fibroblasts after 18 h as previously described ( 13) .
Results
Effects ofrGM-CSF on colonygrowth ofhematopoietic cell lines.
The effects of rGM-CSF on the growth of U937, HL60, KG-1, K562, and Daudi cell lines were evaluated in double layer agar culture in a 2.5-2500 pg/ml rGM-CSF-dose range (Table I) . rGM-CSF did not significantly influence the colony growth or (-7) 89±10 (-1) (Table II) . In contrast to the inhibitory effects of rGM-CSF on U937 proliferation in agar culture, neither recombinant G-CSF nor recombinant M-CSF significantly affected U937 colony growth at dilutions of 1:1,000 or 1:500, respectively (data not shown).
Effects ofrecombinant GM-CSF on proliferation and differentiation of U937 cells in suspension culture. To further characterize the response of the U937 cell line to rGM-CSF, an initial concentration of 3.0 X 105 cells/ml in 10% FBS with RPMI 1640 were incubated in suspension culture, with and without 250 pg/ml rGM-CSF, and evaluated at 0, 24, 48, and 72 h for cell number, cell cycle status, and expression of cell surface markers (Table III and Fig. 1 ). The data in Table III show that anti-proliferative effects of rGM-CSF were rapid, with a 44% decrease in the percentage of cycling cells in combined S, G2, and M cell cycle phases within 24 h. The DNA histograms in Fig. 1 show that rGM-CSF results in a selective reduction of cells in S, G2, M cell-cycle phases, suggesting a block in cell cycle progression at Go or G1. After 72 h ofincubation, it should be noted that the percentage ofcycling cells decreased in control cultures, most likely because of nutrient depletion, although rGM-CSF caused 23% further reduction in the fraction ofcycling cells at this time point.
HLA-DR antigen expression was not induced by rGM-CSF treatment (Table III) (Table III) .
A soluble inhibitor is released by rGM-CSF-treated U937 cells. Since the primary effect of GM-CSF on normal granulocyte-monocyte progenitor cells is to promote proliferation, we considered the possibility that the unusual antiproliferative effects of rGM-CSF on U937 cell growth might be associated with the Figure 2 . Influence of anti-TNF antibody on the inhibitory effect of media conditioned with U937 and rGM-CSF. Media were conditioned with either U937 cells alone, or U937 cells and rGM-CSF (250 pg/ ml), for 24 h. Cell-free supernatants were collected and treated with anti-GM-CSF sheep serum (1: I00 dilution), plus either control antibody (100 jsg/Ml anti-IFN-gamma) or 100 Ag/ml anti-TNF antibody for-1 h at 250C. CM were then added (final concentration 5% vol/vol) to the double-layer colony assay to Assess inhibitory effects on U937 colony growth. Results are from one of three representative experiments.
sence of control antibody, regardless of the source of CM (data not shown). As shown in Fig. 2 , anti-TNF antibody did not affect baseline U937 colony growth in the presence of media conditioned by U937 cells alone. Media conditioned with U937 cells and rGM-CSF was inhibitory to U937 colony growth in the presence of control antibody, but this inhibitory effect was partially reversed in the presence of anti-TNF antibody. These results suggest that TNF was secreted by U937 cells in response to GM-CSF and was partly responsible for the inhibitory effects of media conditioned with rGM-CSF-treated U937 cells. To determine the role of rGM-CSF-induced TNF secretion in the inhibition of U937 colony growth, 100 ,ug/ml anti-TNF-antibody was directly added to agar culture in the presence of 50 or 250 pg/ml rGM-CSF, and U937 colony growth was assessed at day seven. As shown in Table V , anti-TNF-antibody did not significantly alter the inhibitory effects of rGM-CSF on U937 colony growth. This suggests that other soluble inhibitors may mediate this inhibitory effect, that rGM-CSF may exert direct antiproliferative effects on U937 cell growth that are distinct 1Numbers in parentheses indicate percent inhibition.
from its ability to induce TNF secretion, or that it is not possible to add sufficient anti-TNF antibody to observe effects in a 7-d agar culture.
rGM-CSF induces expression ofthe TNF gene in U937 cells and in normal human monocytic cells. To determine if the secretion of TNF by U937 cells was associated with induction of the TNF gene by rGM-CSF, U937 cells were cultured at a starting density of 2.5 X 105 cells/ml 10% FBS with RPMI 1640, with and without 2,500 pg/ml rGM-CSF or 10-10 M PMA, and total cellular RNA was extracted at varying time points. The RNA was fractionated on agarose gels, blotted onto synthetic membranes, and TNF-specific messenger RNA (mRNA) was detected by using a 32P-labeled TNF-specific cDNA probe. Ethidium bromide staining of agarose gels that were used in these studies revealed equivalent amounts of RNA in each lane as assessed by the staining pattern of 18S and 28S ribosomal RNA bands (data not shown). As shown in Fig. 3 , TNF message was induced by rGM-CSF as early as 2 h, with peak expression at 6 h and with detectable levels present at 18 and 24 h. The size of the TNF message detected in U937 cells was similar to that previously reported for PMA-induced HL60 cells (19) . The induction of TNF message by PMA was quantitatively greater than that seen with rGM-CSF, although the size of the message and the kinetics of expression were similar (Fig. 3) .
Since U937 cells have monocytic characteristics, we studied the ability ofrGM-CSF to induce TNF gene expression in normal monocytic cells. To minimize monocyte activation as a result of plastic adherence, E-negative, nonadhered peripheral blood cells were used as a source of human monocytes and were cultured at 2 X 106 cells/ml for 18 h at 37°C in slanted 250-ml polypropylene tubes (Corning Glass Works, Corning Science Products, Corning, NY), with media, mock CSF, or 2,500 pg/ ml rGM-CSF. Polypropylene tubes were used because inactivated human monocytes do not adhere to this surface. Cell recovery and viability was > 90% in all treatment groups. After 18 h of incubation, a small amount of TNIF message was detectable in E-negative cells exposed to either media or mock CSF (Fig. 4) Fig. 3 .
However, significant induction of TNF gene expression was observed in E-negative cells that were exposed to rGM-CSF. As previously stated, the endotoxin concentrations of media, mock CSF, and rGM-CSF were similar, 0.3-0.5 ng/ml, which made it unlikely that the enhanced expression of the TNF gene observed with rGM-CSF was due to contaminating endotoxin. rGM-CSF primes normal human monocytic cells to secrete TNF in response to endotoxin and PMA. To evaluate the effects of rGM-CSF on monocyte TNF secretion, E-negative cells were first cultured at 5 X 106 cells/ml 10% FCS with RPMI 1640 in Linbro 24-well plates with media, rGM-CSF (2,500 pg/mil, heatinactivated rGM-CSF (100°C for 1 h), or mock CSF for either 18 or 72 h. Cell-free supernatants were collected, and TNF was measured by ELISA assay as described. In four separate donors tested, no TNF was detected at 18 or 72 h in any of the four treatment groups outlined above (data not shown). We next considered the possibility that GM-CSF may prime monocytes to secrete TNF in response to a combination of endotoxin and PMA, a known stimulus of TNF secretion (22) . Therefore, monocytes in each of the four treatment groups were incubated for 18 h, washed three times, and divided into two equal fractions that contained either media alone or media plus endotoxin (100 ng/ml) and 10-" M PMA. Cell recovery, viability, and number were equivalent in each of the four treatment groups. Cell-free supernatants were collected after 48 h, and TNF was measured by ELISA assay with the results shown in Fig. 5 . In four separate donors tested, E-negative cells preincubated in media alone (18 h) secreted only a small amount of TNF when exposed to endotoxin and PMA for .48 h. In contrast, E-negative cells that were preincubated with 2,500 pg/ml rGM-CSF secreted greatly enhanced levels of TNF with subsequent endotoxin and PMA exposure. This "priming" effect was specific for rGM-CSF since no effect was observed with preincubation in either heat-inactivated rGM-CSF or mock CSF (Fig. 5) A variety ofstimuli that induce the secretion ofTNF in vitro have been defined. For instance, monocytes and a number of cell lines that include U937 and HL60 secrete TNF after exposure to LPS and/or PMA (27, 28) . Also, the secretion of TNF by human peripheral blood mononuclear cells can be stimulated by a combination of mitogens plus IL-2, and TNF production in this system is enhanced in the presence of IFN-gamma (28) . Furthermore, Sendai virus infection has been recently found to induce TNF secretion by human mononuclear cells (29) . To our knowledge, however, this is the first report that demonstrates the ability of the T cell lymphokine GM-CSF (30) to induce TNF secretion in macrophage-like cells.
In this study, we have also shown that rGM-CSF enhances TNF gene expression in the monocyte-enriched fraction of normal peripheral blood. However, TNF secretion by normal human E-negative cells was not detected after exposure to rGM-CSF for either 18 or 72 h. This suggests that-GM-CSF by itself may not be a sufficient stimulus for monocyte TNF secretion, or that TNF secretion is a transient event occurring at a time point not evaluated in this study. Nevertheless, preincubation of E-negative cells with rGM-CSF was found to significantly enhance their ability to secrete TNF in response to subsequent exposure to endotoxin plus PMA, and a similar priming effect has recently, been reported for CSF-1 (22) . It is possible that a second stimulus such as endotoxin and/or PMA is required to effect efficient translation of the TNF message or to further modify an intracellular, precursor form ofTNF before secretion. Experiments are currently being performed to evaluate these possibilities.
These data suggest that GM-CSF may play a central role in the local immune response. GM-CSF is a lymphokine secreted by activated T cells, and it may be one ofthe factors responsible for priming monocytes to secrete TNF in response to a second stimulus, perhaps physiologically provided by endotoxin. TNF, in turn, has been shown to enhance neutrophil adherence (31) , as well as to kill schistosomula by eosinophils (32) . It has also recently been demonstrated that rGM-CSF induces macrophage tumoricidal activity (5) , and that tumor cell killing by activated macrophages may be mediated by TNF (33) . Altogether, these data suggest that some of the biological effects of GM-CSF on differentiated myeloid cells may be amplified through induction of TNF secretion. Also, TNF is inhibitory to the growth of myeloid progenitor cells, especially in the presence of IFN-gamma (34, 35) , and stimulation of TNF secretion by macrophages in response to GM-CSF may act as a negative feedback circuit in the control of myeloid-cell growth. Further studies of the effect of GM-CSF on TNF secretion by human monocytes will be necessary to better understand the extent to which GM-CSF and TNF may interact in the control of host defense mechanisms and in the regulation of hematopoiesis.
